Cure8 research brief
Clostridium difficile infection is an important and potentially serious complication in ulcerative colitis. A blood‑marker–based risk model could help identify higher‑risk patients noninvasively so clinicians can consider targeted testing or closer monitoring.
Clinicians treating moderate-to-severe ulcerative colitis; researchers in IBD biomarkers and infection risk; adult IBD patients interested in risk prediction tools.
This open‑access study developed and internally validated a risk prediction model (nomogram) using seven serological markers to identify patients with moderate-to-severe ulcerative colitis at higher risk of concurrent Clostridium difficile infection (CDI).
The authors retrospectively analyzed 252 patients and used LASSO regression to select independent risk factors including cholesterol, LDL, uric acid, fibrinogen, lower hemoglobin, use of biologic agents, and an LDL–fibrinogen ratio.
The reported model discrimination (AUC/C‑index ≈ 0.789) and tenfold cross‑validation results suggest moderate accuracy, but the paper emphasizes need for external validation. The article is a retrospective, single‑center diagnostic/predictive study rather than a randomized trial.
Results describe associations and a statistical risk tool, not proven clinical outcomes from interventions guided by the model. The study explicitly names biologic therapies (infliximab, vedolizumab, ustekinumab) among recorded variables; it does not provide treatment recommendations.
The study is retrospective and internally validated only; external validation and prospective studies are needed before applying the nomogram in routine care.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: National Natural Science Foundation of China, award Grant No. 82060448 and 82360112; Jiangxi Provincial Traditional Chinese Medicine Administration Science and Technology Plan Project, award Grant No.2024A0032
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Kidney dysfunction can occur in people with IBD and may be under-recognized. A validated prediction model could help clinicians identify IBD patients at higher risk and prompt earlier monitoring or interventions.
CMV reactivation can worsen outcomes in active UC and influence treatment choices; clinicians and patients may benefit from additional, easy-to-measure markers that flag higher risk of tissue CMV and prompt targeted...
If you or a patient is about to start infliximab for ulcerative colitis, routine blood counts may help identify those unlikely to respond to induction therapy; a high negative predictive value suggests these markers...
